The Effect of STW5 (Iberogast) on Reflux Symptoms in Patients With Concurrent Dyspeptic Symptoms: A Double-blind Randomized Placebo-controlled Crossover Trial.

ABSTRACT:

Background/aims

It has been suggested that STW5 (Iberogast) reduces heartburn symptoms in patients with functional dyspepsia, but underlying mechanisms of action are unclear. The aim of this study is to investigate whether STW5 affects esophageal sensitivity or esophageal motility, thereby reducing occurrence and perception of reflux events.

Methods

We performed a double-blind, randomized, placebo-controlled, crossover trial in patients with functional dyspepsia (Rome IV) and reflux symptoms. After 4 weeks of treatment with either placebo or STW5, patients were studied with an esophageal acid perfusion test and ambulatory 24-hour pH-impedance monitoring.

Results

A total of 18 patients (7 men, median age 54, range [19-76]), were included in the study. Although we found

SUBMITTER: Oude Nijhuis RAB 

PROVIDER: S-EPMC10774799 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature